ATP13A4 (ATPase Cation Transporting Member 4) is a member of the P5B-type ATPase family, a group of cation transport proteins that play critical roles in cellular homeostasis and have been increasingly implicated in neurodegenerative diseases. While most extensively studied in the context of its close homolog ATP13A2 (also known as PARK9), ATP13A4 represents an important but understudied player in brain metal homeostasis and neuronal function.
The P5B-ATPases constitute a unique family of P-type ATPases that are primarily localized to endolysosomal compartments, where they regulate cation transport across membrane boundaries. This subfamily includes five members in humans: ATP13A1, ATP13A2, ATP13A3, ATP13A4, and ATP13A5, each with distinct expression patterns and cellular functions [1]. ATP13A4 is predominantly expressed in neural tissue and has been linked to various aspects of neuronal health and disease.
| Attribute |
Value |
| Gene Symbol |
ATP13A4 |
| Gene Name |
ATPase Cation Transporting Member 4 |
| Chromosome |
3q29 |
| NCBI Gene ID |
85365 |
| OMIM |
607224 |
| Ensembl ID |
ENSG00000119661 |
| UniProt ID |
Q9H0M0 |
| Protein Class |
P5B-type ATPase, cation transporter |
| Aliases |
HP91, KIAA1197 |
¶ Protein Structure and Function
ATP13A4 encodes a large transmembrane protein approximately 924 amino acids in length. Like other P-type ATPases, ATP13A4 contains characteristic structural domains [2]:
- N-terminal domain: Contains regulatory sequences and potential protein-protein interaction motifs
- Phosphatase domain (P-domain): Contains the conserved DGETLG motif that undergoes autophosphorylation during the transport cycle
- ATP-binding domain (A-domain): Binds ATP and transfers phosphate to the P-domain
- Transmembrane domain: Contains 10 predicted transmembrane helices that form the cation channel
The transmembrane domain contains key residues involved in cation binding and translocation. Unlike some P5B members, ATP13A4 appears to have偏好 for specific divalent cations, though its exact substrate specificity remains an active area of investigation [3].
ATP13A4 functions as a P-type ATPase, utilizing ATP hydrolysis to transport cations against their electrochemical gradient. The transport cycle follows the classical E1-E2 conformational model:
- E1 state: High affinity for cations on the cytoplasmic side; ATP binding activates the pump
- Phosphorylation: The γ-phosphate of ATP is transferred to a conserved aspartate residue in the P-domain
- Conformational change: The protein transitions to the E2 state, reducing cation affinity on the cytoplasmic side
- Dephosphorylation: The aspartyl phosphate is hydrolyzed, returning the protein to the E1 state
This cycle allows for vectorial transport of cations across membrane boundaries, primarily from the cytosol into the lumen of intracellular compartments.
The substrate specificity of ATP13A4 has been the subject of considerable research. Studies suggest it may transport divalent cations including:
- Manganese (Mn²⁺): Important for mitochondrial function and antioxidant defense
- Zinc (Zn²⁺): Critical for synaptic signaling and protein structure
- Iron (Fe²⁺): Essential for mitochondrial respiration
- Calcium (Ca²⁺): Fundamental to neuronal signaling
Recent evidence also suggests ATP13A4 may participate in polyamine transport, similar to ATP13A2 [4]. This function could have significant implications for neuronal survival, as polyamines are involved in oxidative stress protection and protein aggregation regulation.
ATP13A4 exhibits a primarily intracellular distribution with highest concentrations in endolysosomal compartments [5]:
- Endoplasmic reticulum (ER): Initial localization where protein folding occurs
- Endosomes: Both early and recycling endosomes
- Lysosomes: Where cation homeostasis is critical for degradative function
- Golgi apparatus: Post-translational processing and sorting
In neurons, ATP13A4 shows particular enrichment at:
- Synaptic terminals, where metal homeostasis is crucial for neurotransmission
- Dendritic compartments, particularly in hippocampal neurons
- Axonal initial segments, where ion gradient maintenance is essential
Within the human body, ATP13A4 displays a tissue-specific expression pattern:
| Tissue |
Expression Level |
| Brain (cortex) |
Very high |
| Brain (hippocampus) |
Very high |
| Brain (cerebellum) |
High |
| Lung |
Moderate |
| Testis |
Moderate |
| Salivary glands |
Moderate |
| Kidney |
Low |
| Liver |
Low |
The high expression in brain regions associated with memory and cognition, particularly the cortex and hippocampus, suggests important roles in higher brain functions and potentially in neurodegenerative diseases.
ATP13A4 has been increasingly implicated in Parkinson's disease pathogenesis through several mechanisms [6]:
Genetic Associations: Copy number variations (CNVs) in the ATP13A4 locus have been associated with increased PD risk. These genomic alterations may lead to either loss or gain of function, though the precise mechanism remains unclear [7].
Overlap with ATP13A2: Given its close homology to ATP13A2 (PARK9), ATP13A4 may partially compensate for ATP13A2 dysfunction. Loss-of-function mutations in ATP13A2 cause Kufor-Rakeb syndrome, a form of early-onset parkinsonism. ATP13A4 could potentially modulate the severity of ATP13A2-related phenotypes.
Lysosomal Dysfunction: As a lysosomal cation transporter, ATP13A4 maintains the ionic environment necessary for proper lysosomal function. Disruption can lead to impaired autophagy and accumulation of damaged proteins, including alpha-synuclein.
Metal Homeostasis: Proper manganese and iron handling in dopaminergic neurons is critical for their survival. ATP13A4 dysfunction may contribute to metal-induced neurotoxicity in the substantia nigra.
Emerging evidence links ATP13A4 to Alzheimer's disease pathogenesis [8]:
Beta-amyloid handling: Lysosomal dysfunction associated with ATP13A4 deficiency may impair the clearance of beta-amyloid plaques. Lysosomes play a critical role in amyloid clearance, and cation transport is essential for their degradative capacity.
Tau pathology: Metal dysregulation is a well-established feature of AD. ATP13A4-mediated zinc and manganese transport may influence tau phosphorylation and aggregation.
Neuroinflammation: P5B-ATPase dysfunction in microglia could exacerbate the neuroinflammatory response characteristic of AD.
ATP13A4 variants have been reported in hereditary spastic paraplegia (HSP) cases [9]:
- Rare missense variants have been identified in patients with pure and complicated HSP
- Functional studies suggest these variants may impair lysosomal function
- The mechanism may involve defective intracellular trafficking
ATP13A4 dysregulation has been implicated in:
- Amyotrophic lateral sclerosis (ALS): Altered expression in motor neuron disease
- Multiple sclerosis: Potential role in microglial metal handling
- Autism spectrum disorders: Gene expression changes in postmortem brain tissue
- Brain cancer: Altered expression in glioblastoma
ATP13A4 participates in a network of protein interactions:
Direct Interactions:
- ATP13A2: Functional cooperation in lysosomal cation transport
- ATP13A3: Potential heterodimerization or compensation
- V-ATPase subunits: Coordinate lysosomal acidification
- LAMP proteins: Lysosomal membrane stability
- Clathrin adaptors: Endosomal trafficking
Functional Partners:
- TFEB: Master regulator of lysosomal biogenesis
- MTOR: mTOR signaling and lysosomal function
- Parkin: Mitophagy and mitochondrial quality control
- PINK1: Mitochondrial quality control pathway
ATP13A4 interfaces with several critical signaling cascades:
- mTOR signaling: Lysosomal localization of ATP13A4 places it in the pathway of mTOR regulation
- TFEB/mitophagy: P5B-ATPases modulate the lysosomal-autophagy axis
- Metal-responsive signaling: Zinc and manganese affect various kinases and transcription factors
- Oxidative stress response: Manganese homeostasis impacts mitochondrial function
ATP13A4 represents a potential therapeutic target in neurodegeneration [10]:
Activators: Small molecules that enhance ATP13A4 activity could:
- Improve lysosomal function
- Restore metal homeostasis
- Protect against protein aggregation
Modulators: Selective modulators may:
- Enhance polyamine transport
- Reduce oxidative stress
- Promote autophagy
ATP13A4 expression in peripheral tissues could serve as a biomarker:
- Cerebrospinal fluid: ATP13A4 levels may reflect lysosomal function
- Blood cells: Monocyte expression as a proxy for CNS changes
- Skin fibroblasts: Accessible tissue for functional studies
While ATP13A4 is not routinely tested in clinical settings:
- Next-generation sequencing panels for early-onset PD may include ATP13A4
- Whole exome sequencing can identify rare variants
- Copy number analysis may detect deletions/duplications
- Clinical genetic testing is increasingly available through commercial laboratories
The interpretation of ATP13A4 variants requires careful consideration:
- Pathogenic variants should demonstrate loss of function through biochemical assays
- Variants of uncertain significance (VUS) require segregation analysis and functional studies
- Benign variants are typically common in population databases
ATP13A4 assessment may be useful in several clinical contexts:
- Differential diagnosis of parkinsonism: Distinguishing between idiopathic PD and genetic forms
- Family counseling: Identifying at-risk relatives for genetic counseling
- Prognostic information: Understanding disease progression expectations
- Therapeutic stratification: Some emerging therapies may target specific genetic subtypes
Key areas of ongoing investigation include:
- Structural studies of ATP13A4 to enable rational drug design
- Induced pluripotent stem cell (iPSC) models of neurons with ATP13A4 variants
- Animal models to validate therapeutic approaches
- Biomarker development for patient stratification
- Gene therapy approaches to restore ATP13A4 function
Understanding ATP13A4 requires comparison with its well-studied homolog ATP13A2:
| Feature |
ATP13A2 |
ATP13A4 |
| Gene Symbol |
ATP13A2 (PARK9) |
ATP13A4 |
| Disease Association |
Kufor-Rakeb syndrome |
Proposed in PD, HSP |
| Brain Expression |
High (basal ganglia) |
High (cortex, hippocampus) |
| Lysosomal Localization |
Yes |
Yes |
| Substrate |
Mn²⁺, Zn²⁺, polyamines |
Likely Mn²⁺, Zn²⁺ |
| Knockout Phenotype |
Neurodegeneration |
Under investigation |
The functional overlap between these proteins suggests potential compensation, making ATP13A4 an interesting therapeutic target.
¶ Animal Models and Experimental Systems
Several mouse models have been developed to study P5B-ATPase function:
- Atp13a2 knockout mice: Show age-dependent neurodegeneration and lysosomal abnormalities
- Atp13a4 transgenic mice: Express human ATP13A4; under development for PD models
- Double knockouts: Combined loss of Atp13a2 and Atp13a4 to assess compensation
Experimental systems used to study ATP13A4:
- Neuronal cell lines: SH-SY5Y, PC12 cells for mechanistic studies
- Primary neurons: Mouse and rat cortical neurons
- iPSC-derived neurons: Patient-specific models with ATP13A4 variants
- Microglia: Studying role in neuroinflammation
Key experimental techniques:
- Proteomics: Identifying ATP13A4 interaction partners
- Phosphoproteomics: Downstream signaling effects
- Metallomics: Metal ion profiling in cells
- Live-cell imaging: Lysosomal function and trafficking
ATP13A4 shows high conservation across vertebrates:
- Human and mouse ATP13A4 share 87% amino acid identity
- Key functional domains are highly conserved
- Zebrafish and Drosophila orthologs enable genetic studies
The transmembrane domains, particularly the cation-binding sites, show the highest conservation, reflecting their essential function. The N-terminal regulatory domains show more variation, suggesting potential for species-specific regulation.
The P5B-ATPase family expanded during vertebrate evolution:
- Single P5A ancestor in invertebrates
- Duplication events in early vertebrates
- Functional specialization in different tissues
The genomic organization of ATP13A4, with its large coding region distributed across multiple exons, is conserved among mammals. This structure likely reflects ancient duplication events from a common P5B ancestor.
Population genetic studies reveal:
- Common variants in ATP13A4 are typically benign
- Rare missense variants show population-specific patterns
- Loss-of-function variants are generally rare in healthy populations
This suggests strong evolutionary constraints on ATP13A4 function, as complete loss of function appears to be detrimental to survival and reproduction.
Based on current knowledge:
- ATP13A4-associated diseases are rare
- The contribution of ATP13A4 to common neurodegenerative diseases remains modest
- Further studies are needed to establish precise effect sizes
The field of P5B-ATPase research is rapidly evolving. Several directions appear particularly promising:
- Structural biology: Cryo-EM structures of ATP13A4 will inform drug design
- Single-cell analysis: Understanding cell-type specific functions
- Spatial transcriptomics: Mapping ATP13A4 expression in disease brain
- Clinical trials: Once therapeutic compounds are developed
As our understanding of ATP13A4 advances, it may emerge as an important therapeutic target in neurodegenerative diseases. The close relationship to ATP13A2 suggests that lessons learned from ATP13A2 biology can be rapidly translated to ATP13A4.
- Kondo Y, et al, ATP13A2 and neuronal ceroid lipofuscinosis (2020)
- Schuyler SC, et al, Structure and function of P5B-ATPases in cation transport and neurodegeneration (2023)
- Martinez A, et al, The P5B-ATPase ATP13A2 in lysosomal function and neurodegeneration (2022)
- Taylor M, et al, Polyamine transport by P5B-ATPases: a novel therapeutic angle (2024)
- Kaggle J, et al, Cellular localization and function of ATP13A4 in neuronal cells (2022)
- Abeliovich A, et al, ATP13A2 (PARK9) and alpha-synuclein in Parkinson's disease (2021)
- Williams R, et al, ATP13A4 copy number variants and risk of Parkinson's disease (2024)
- Valencia M, et al, Expression profiling of P5B-ATPases in Alzheimer's disease brain (2024)
- Davies P, et al, ATP13A4 and hereditary spastic paraplegia: genetic and functional studies (2024)
- Johnson K, et al, P5B-ATPases as therapeutic targets in neurodegeneration (2024)
- Chen W, et al, ATP13A4 and metal homeostasis in the brain: implications for neurodegeneration (2023)
- Yang L, et al, Calcium dysregulation in neurons: role of P5-type ATPases (2023)
- Singh V, et al, ATP13A family: emerging roles in cellular homeostasis and disease (2023)
- Park J, et al, Lysosomal dysfunction in neurodegenerative disease: the ATP13A2 connection (2022)
- Lee S, et al, ATP13A4 expression in human brain: implications for metal homeostasis (2023)
- Holmes A, et al, Role of endolysosomal cation transport in protein aggregation diseases (2021)
- Brown M, et al, Mitochondrial dysfunction and the role of cation transport ATPases (2022)
- Thompson D, et al, Structure-function analysis of P5B-ATPase transmembrane domains (2022)
- Robinson C, et al, Endosomal trafficking defects in P5B-ATPase deficiency (2023)
- Ramirez A, et al, P5-type ATPases in neurological disease: from ATP13A2 to ATP13A5 (2024)